Ozempic (semaglutide) is generally well-tolerated, but like all medications, it comes with side effects. Some are common and temporary. Others are rare but serious. Knowing what to expect — and when to be concerned — helps you use the medication safely and make informed decisions with your healthcare provider.
This guide covers everything from the first-week nausea to long-term safety data, drawn from clinical trials involving over 8,000 patients and post-marketing surveillance.
What Most People Experience
The most frequently reported side effects are gastrointestinal, occurring primarily during the dose-escalation phase (first 8-16 weeks). These are a direct consequence of how the drug works — slowing gastric emptying and altering gut signaling.
| Side Effect | Frequency | Typical Duration | Management |
|---|---|---|---|
| Nausea | 15–20% | 4–8 weeks | Eat smaller meals, avoid fatty/fried foods, stay hydrated |
| Diarrhea | 8–9% | 2–6 weeks | Stay hydrated, avoid high-fiber and spicy foods initially |
| Vomiting | 5–9% | 2–4 weeks | Eat bland foods, avoid large meals, contact doctor if persistent |
| Constipation | 3–5% | Variable | Increase water and fiber intake, consider stool softener |
| Abdominal pain | 5–7% | 2–6 weeks | Eat slowly, reduce portion sizes |
| Injection site reactions | 0.2% | Hours to days | Rotate injection sites, apply cold compress |
| Headache | 1–3% | 1–2 weeks | Stay hydrated, OTC pain relief as needed |
| Fatigue | 1–3% | Variable | Ensure adequate caloric intake, rest |
The Good News
For the majority of patients, GI side effects peak during the first dose escalation and improve substantially by week 8. In the SUSTAIN trials, only about 4-5% of patients discontinued semaglutide due to GI side effects — meaning 95% found them manageable.
Why Nausea Happens — and Why It Fades
Nausea is the hallmark side effect of GLP-1 agonists. It occurs because semaglutide slows gastric emptying and activates nausea-related receptors in the brainstem (area postrema). As your body adjusts to the medication — a process called tachyphylaxis — these receptors become less sensitive, and nausea diminishes.
This is precisely why the dosing schedule is gradual: starting at 0.25 mg (a sub-therapeutic dose) for 4 weeks gives your GI system time to adapt before moving to the therapeutic 0.5 mg dose.
Rare but Important Risks
While uncommon, these side effects require medical attention:
Pancreatitis
Inflammation of the pancreas has been reported in 0.1-0.3% of patients taking semaglutide in clinical trials. Symptoms include severe, persistent abdominal pain (often radiating to the back), nausea, and vomiting. The mechanism is not fully understood but may relate to GLP-1's effects on pancreatic duct cells. Patients with a history of pancreatitis should discuss this risk carefully with their provider.
Gallbladder Disease
Rapid weight loss from any cause increases the risk of gallstones. In the SUSTAIN and STEP trials, cholelithiasis (gallstones) occurred in 1.5-2.6% of semaglutide-treated patients compared to 0.4-1.0% on placebo. Symptoms include right upper abdominal pain, especially after fatty meals, and nausea. Some cases required cholecystectomy (gallbladder removal).
Acute Kidney Injury
Reported in post-marketing surveillance, typically secondary to dehydration from severe vomiting or diarrhea. Patients with pre-existing kidney disease are at higher risk. Monitoring kidney function and maintaining adequate hydration are important, especially during dose escalation when GI symptoms are most likely.
Diabetic Retinopathy Complications
SUSTAIN 6 found a statistically significant increase in diabetic retinopathy complications (3.0% vs 1.8% on placebo). This is thought to be related to the speed of blood sugar improvement rather than a direct drug effect — rapid A1C reduction can temporarily worsen existing retinopathy. Patients with existing diabetic retinopathy should have eye exams before starting and during treatment.
Hypoglycemia
When used alone, Ozempic carries a low risk of hypoglycemia due to its glucose-dependent mechanism. However, when combined with insulin or sulfonylureas, the risk increases significantly. Dose adjustments of those medications may be necessary.
Thyroid C-Cell Tumor Risk
⚠️ FDA Boxed Warning
In rodent studies, semaglutide caused dose-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Ozempic is contraindicated in patients with:
- A personal or family history of MTC
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
It's important to note that the relevance to humans remains uncertain. Rodent thyroid C-cells have a much higher density of GLP-1 receptors than human C-cells, making the rodent model imperfect for predicting human risk. Large epidemiological studies and the SUSTAIN trial program have not detected an increased rate of MTC in humans. However, the risk cannot be fully excluded, which is why the boxed warning remains.
Report any lump or swelling in your neck, hoarseness, difficulty swallowing, or shortness of breath to your healthcare provider immediately.
What We Know After Years of Data
Semaglutide has been on the market since 2017 (Ozempic) and studied in clinical trials since 2012. The long-term safety profile is reassuring for most patients, but some areas are still under investigation:
Confirmed Long-Term Safety
- Cardiovascular: SUSTAIN 6 and SELECT trial data demonstrate cardiovascular benefit, not harm, over 2-5 years
- Metabolic: Sustained A1C reductions and weight loss maintained over 2+ years of continuous use
- No increased cancer risk: Large-scale analyses have not found increased overall cancer incidence with GLP-1 agonists in humans
Areas Still Under Study
- Thyroid cancer risk in humans: No signal detected, but ongoing monitoring continues
- Pancreatic cancer: No causal association established, but monitoring continues given theoretical concerns
- Mental health effects: FDA investigating reports of suicidal ideation with GLP-1 agonists. Large studies to date (including a 2024 Nature Medicine analysis) have not found increased risk
- Bone density: Rapid weight loss can affect bone density; long-term effects of GLP-1-associated weight loss on fracture risk remain under study
- Muscle mass: Weight loss includes 30-40% lean mass. Long-term impact on sarcopenia risk is being evaluated
Comparison Across Doses
| Side Effect | 0.25 mg | 0.5 mg | 1 mg | 2 mg |
|---|---|---|---|---|
| Nausea | 7% | 12% | 16% | 20% |
| Diarrhea | 4% | 6% | 8% | 9% |
| Vomiting | 2% | 4% | 6% | 9% |
| Constipation | 2% | 3% | 4% | 5% |
| Abdominal pain | 3% | 5% | 6% | 7% |
| Discontinuation due to AEs | 1% | 3% | 4% | 5% |
Data from SUSTAIN trial program. Percentages are approximate and vary across trials.
When to Call Your Doctor
Seek Immediate Medical Attention If You Experience:
- Severe abdominal pain that doesn't go away — may indicate pancreatitis
- Signs of allergic reaction — swelling of face, lips, tongue, or throat; difficulty breathing; rash
- Vision changes — blurred vision, floaters, or sudden vision loss (possible retinopathy complications)
- Kidney problems — decreased urination, swelling in feet/ankles, confusion
- Lump in your neck — possible thyroid issue, especially with hoarseness or difficulty swallowing
- Signs of severe hypoglycemia — shakiness, rapid heartbeat, confusion, loss of consciousness
Contact your doctor (non-emergency) if:
- Nausea, vomiting, or diarrhea is persistent (lasting more than 3 days) or severe enough to prevent eating/drinking
- You notice unexplained mood changes, anxiety, or depressive symptoms
- You experience right upper abdominal pain after eating (possible gallstones)
- You have heart rate changes (semaglutide can increase resting heart rate by 1-4 bpm on average)
- You notice significant hair thinning (may indicate telogen effluvium from rapid weight loss)
Managing Side Effects
During Dose Escalation (First 8-16 Weeks)
- Eat smaller, more frequent meals — 4-5 small meals instead of 3 large ones
- Avoid trigger foods — fatty, fried, greasy, and very spicy foods worsen nausea
- Stay hydrated — sip water throughout the day. Dehydration from GI symptoms is the most common cause of complications
- Time your injection — some patients find injecting in the evening helps them sleep through initial nausea
- Don't skip the starting dose — 0.25 mg for 4 weeks isn't optional. It lets your body adjust
- Ginger can help — ginger tea or supplements have evidence for nausea relief
Ongoing
- Prioritize protein — aim for 1.2-1.6 g/kg body weight daily to minimize muscle loss
- Strength training — resistance exercise preserves lean mass during weight loss
- Monitor your diet quality — reduced appetite means each calorie counts more. Focus on nutrient-dense foods
- Keep follow-up appointments — regular monitoring helps catch rare complications early
Frequently Asked Questions
Sources
- FDA. "Ozempic (semaglutide) injection Prescribing Information." FDA Label
- Marso SP, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." N Engl J Med. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021;384:989-1002. doi:10.1056/NEJMoa2032183
- Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
- Wang W, et al. "Association of semaglutide with risk of suicidal ideation in a real-world cohort." Nat Med. 2024;30:168-176. doi:10.1038/s41591-023-02672-2
- Sorli C, et al. "Efficacy and safety of once-weekly semaglutide monotherapy versus placebo (SUSTAIN 1)." Lancet Diabetes Endocrinol. 2017;5(4):251-260.
- Novo Nordisk. "SUSTAIN clinical trial program results." novonordisk.com